Login to Your Account


Biogen Receives Approval For Amevive, Signs Deal With IDEC

By Brady Huggett


Monday, February 3, 2003
Ushering in what Biogen Inc. CEO and chairman James Mullen called "an exciting time for us and hopefully an exciting time for our investors," the FDA approved Biogen's Amevive for psoriasis, giving Biogen the first biologic treatment for that indication. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.